Research Paper Volume 16, Issue 8 pp 6773—6795

Figure 1. HAPSTR1 was overexpressed in ovarian cancer tissues and closely related to clinical outcome. (A) Clinical samples in Cohort 1 were used to detect mRNA expression levels of HAPSTR1, including 18 normal ovarian tissues, 9 borderline ovarian tumors, and 40 primary ovarian cancer specimens. (B) An immunohistochemistry assay was used to detect protein expression levels of HAPSTR1 in Cohort 2, including 47 epithelial ovarian cancer and 19 normal ovarian tissues. (C) IHC results of Cohort 2 showed HAPSTR1 expression was related to FIGO stage. Original magnification, 200X, 400X. (D) Kaplan–Meier survival analysis of overall and progression-free survival in patients with ovarian cancer. (E) The relationship between HAPSTR1 expression and infiltration levels in the TIMER database. (F–H) Results from the TISCH database showed a relationship between HAPSTR1 expression levels and immune cells. Each experiment was repeated with three independent replicates. *, p < 0.05; **, p < 0.01; ***, p < 0.001.